Evidence map›Paper›PMID 24626195›Full record

ArticlePLoS pathogens2014

Clonality of HTLV-2 in natural infection.

Anat Melamed, Aviva D Witkover, Daniel J Laydon, Rachael Brown, Kristin Ladell, Kelly Miners, Aileen G Rowan, Niall Gormley, David A Price, Graham P Taylor and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. HTLV-2 Enhances CD8Viruses · 2022
    Article
  4. Article
  5. SomaticHaematologica · 2022
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Time to Go Back to the Original Name.Frontiers in microbiology · 2017
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Clonality and intracellular polyploidy in virus evolution and pathogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Anat MelamedSection of Immunology, Imperial College London, Wright-Fleming Institute, London, United Kingdom.
Aviva D WitkoverSection of Immunology, Imperial College London, Wright-Fleming Institute, London, United Kingdom.
Daniel J LaydonSection of Immunology, Imperial College London, Wright-Fleming Institute, London, United Kingdom.
Rachael BrownSection of Immunology, Imperial College London, Wright-Fleming Institute, London, United Kingdom.
Kristin LadellInstitute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
Kelly MinersInstitute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
Aileen G RowanSection of Immunology, Imperial College London, Wright-Fleming Institute, London, United Kingdom.
Niall GormleyIllumina, Little Chesterford, Essex, United Kingdom.
David A PriceInstitute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
Graham P TaylorSection of Infectious Diseases, Imperial College London, Wright-Fleming Institute, London, United Kingdom.
Edward L MurphyDepartments of Laboratory Medicine and Epidemiology/Biostatistics, University of California San Francisco and Blood Systems Research Institute, San Francisco, California, United States of America.
Charles R M BanghamSection of Immunology, Imperial College London, Wright-Fleming Institute, London, United Kingdom.
Imperial College London · GBCardiff University · GBIllumina (United Kingdom) · GBUniversity of California, San Francisco · US

Funding

Medical Research Council MR/K019090/1Wellcome Trust 100291Wellcome Trust 100326
6 · The paper itself

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) both cause lifelong persistent infections, but differ in their clinical outcomes. HTLV-1 infection causes a chronic or acute T-lymphocytic malignancy in up to 5% of infected individuals whereas HTLV-2 has not been unequivocally linked to a T-cell malignancy. Virus-driven clonal proliferation of infected cells both in vitro and in vivo has been demonstrated in HTLV-1 infection. However, T-cell clonality in HTLV-2 infection has not been rigorously characterized. In this study we used a high-throughput approach in conjunction with flow cytometric sorting to identify and quantify HTLV-2-infected T-cell clones in 28 individuals with natural infection. We show that while genome-wide integration site preferences in vivo were similar to those found in HTLV-1 infection, expansion of HTLV-2-infected clones did not demonstrate the same significant association with the genomic environment of the integrated provirus. The proviral load in HTLV-2 is almost confined to CD8+ T-cells and is composed of a small number of often highly expanded clones. The HTLV-2 load correlated significantly with the degree of dispersion of the clone frequency distribution, which was highly stable over ∼8 years. These results suggest that there are significant differences in the selection forces that control the clonal expansion of virus-infected cells in HTLV-1 and HTLV-2 infection. In addition, our data demonstrate that strong virus-driven proliferation per se does not predispose to malignant transformation in oncoretroviral infections.

Indexed as

CD8-Positive T-LymphocytesClone CellsComputational BiologyFlow CytometryHigh-Throughput Screening AssaysHTLV-II InfectionsHTLV-I InfectionsHumansHuman T-lymphotropic virus 1Human T-lymphotropic virus 2ProvirusesReverse Transcriptase Polymerase Chain ReactionViral LoadVirus Integration

Identifiers

PMID24626195
PMCPMC3953477
OpenAlexW2047340476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.